S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
S&P 500   4,221.02
DOW   33,061.57
QQQ   352.01
Stock market today: Asia follows Wall St up on hopes Fed will ease off rate hikes
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Is This The Collapse of Icahn Enterprises ?
20 Best Healthcare Dividend Stocks to Invest in
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Money stored in Venmo and other payment apps could be vulnerable, financial watchdog warns
Nordstrom's Earnings Beat, A Rally In The Making
Lithium Has Boomed And This American Stock Is Ready.. (Ad)
Elliott Management Says Goodyear Tire Worth At Least $21 a Share
What Does the Airbnb Guidance Drop Say About Travel Demand?
NYSE:ADCT

ADC Therapeutics (ADCT) Stock Forecast, Price & News

$2.38
+0.03 (+1.28%)
(As of 06/1/2023 ET)
Compare
Today's Range
$2.31
$2.50
50-Day Range
$1.90
$2.66
52-Week Range
$1.85
$10.88
Volume
195,716 shs
Average Volume
576,970 shs
Market Capitalization
$182.81 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.17

ADC Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
327.2% Upside
$10.17 Price Target
Short Interest
Bearish
9.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.20mentions of ADC Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.73) to ($2.49) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

905th out of 1,980 stocks

Pharmaceutical Preparations Industry

433rd out of 978 stocks


ADCT stock logo

About ADC Therapeutics (NYSE:ADCT) Stock

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Receive ADCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ADCT Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Free Stock Analysis Report: See The True Value of Any Stock
Get a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation.
ADC Therapeutics (ADCT) Receives a Buy from RBC Capital
See More Headlines

ADCT Price History

ADCT Company Calendar

Last Earnings
11/02/2021
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
312
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.17
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+327.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$-155,800,000.00
Net Margins
-108.86%
Pretax Margin
-107.74%

Debt

Sales & Book Value

Annual Sales
$209.91 million
Book Value
$0.49 per share

Miscellaneous

Free Float
49,619,000
Market Cap
$182.81 million
Optionable
Not Optionable
Beta
1.10

Key Executives

  • Dr. Ameet Mallik M.B.A. (Age 51)
    M.S., CEO & Director
  • Dr. Christopher J. Martin DPHIL (Age 64)
    Ph.D., Co-Founder & Non-Exec. Director
  • Mr. Jose I. Carmona M.B.A. (Age 51)
    Chief Financial Officer
  • Dr. Michael Mulkerrin Ph.D.
    Chief Technical Operations Officer
  • Dr. Patrick van Berkel Ph.D. (Age 55)
    Chief Scientific Officer
  • Amanda Hamilton
    Investor Relations Officer
  • Ms. Susan Romanus (Age 58)
    Chief Compliance & Quality Officer
  • Mr. Peter J. Graham Esq. (Age 56)
    Chief Legal Officer
  • Ms. Kimberly Pope (Age 57)
    Sr. VP & Chief People Officer
  • Dr. Joseph Camardo Ph.D. (Age 70)
    Chief Medical Officer













ADCT Stock - Frequently Asked Questions

Should I buy or sell ADC Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ADC Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ADCT shares.
View ADCT analyst ratings
or view top-rated stocks.

What is ADC Therapeutics' stock price forecast for 2023?

6 brokers have issued twelve-month price targets for ADC Therapeutics' stock. Their ADCT share price forecasts range from $5.00 to $20.00. On average, they expect the company's share price to reach $10.17 in the next year. This suggests a possible upside of 327.2% from the stock's current price.
View analysts price targets for ADCT
or view top-rated stocks among Wall Street analysts.

How have ADCT shares performed in 2023?

ADC Therapeutics' stock was trading at $3.84 at the start of the year. Since then, ADCT shares have decreased by 38.0% and is now trading at $2.38.
View the best growth stocks for 2023 here
.

Are investors shorting ADC Therapeutics?

ADC Therapeutics saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 6,160,000 shares, a decline of 17.1% from the April 30th total of 7,430,000 shares. Based on an average daily trading volume, of 611,200 shares, the days-to-cover ratio is currently 10.1 days. Approximately 9.8% of the company's shares are short sold.
View ADC Therapeutics' Short Interest
.

When is ADC Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our ADCT earnings forecast
.

How were ADC Therapeutics' earnings last quarter?

ADC Therapeutics SA (NYSE:ADCT) released its earnings results on Tuesday, November, 2nd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by $0.01. The company had revenue of $13.15 million for the quarter, compared to analyst estimates of $7.74 million. ADC Therapeutics had a negative trailing twelve-month return on equity of 229.20% and a negative net margin of 108.86%. During the same period last year, the company posted ($0.29) earnings per share.

What other stocks do shareholders of ADC Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADC Therapeutics investors own include CVS Health (CVS), Raytheon Technologies (RTX), Home Depot (HD), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Alibaba Group (BABA), Cisco Systems (CSCO), Johnson & Johnson (JNJ) and CSX (CSX).

When did ADC Therapeutics IPO?

(ADCT) raised $126 million in an initial public offering (IPO) on Friday, May 15th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities and Cowen and Company acted as the underwriters for the IPO.

What is ADC Therapeutics' stock symbol?

ADC Therapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "ADCT."

Who are ADC Therapeutics' major shareholders?

ADC Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Prosight Management LP (4.24%), JPMorgan Chase & Co. (4.03%), Sio Capital Management LLC (2.81%), Bank of America Corp DE (2.14%), Perceptive Advisors LLC (1.95%) and Pictet Asset Management SA (1.78%).

How do I buy shares of ADC Therapeutics?

Shares of ADCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADC Therapeutics' stock price today?

One share of ADCT stock can currently be purchased for approximately $2.38.

How much money does ADC Therapeutics make?

ADC Therapeutics (NYSE:ADCT) has a market capitalization of $182.81 million and generates $209.91 million in revenue each year. The company earns $-155,800,000.00 in net income (profit) each year or ($2.53) on an earnings per share basis.

How many employees does ADC Therapeutics have?

The company employs 312 workers across the globe.

How can I contact ADC Therapeutics?

The official website for the company is www.adctherapeutics.com. The company can be reached via phone at 41-21-653-0200 or via email at amanda.hamilton@adctherapeutics.com.

This page (NYSE:ADCT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -